

Karyopharm Therapeutics Investor Relations Department 85 Wells Ave, 2nd floor Newton, MA 02459 United States

Visit IR website ☐ Sign-up for Email alerts ☐

| NASDAQ: KPTI | |
|---------------|----------------------------|
| Last Trade: | 9.39 |
| Trade Time: | 1:13 PM ET Jun 27, 2017 |
| Change: | -0.13 🖶 (-1.366%) |
| Day Range | 9.36 - 9.58 |
| 52-Week Range | 6.27 - 14.63 |
| Volume | 63,840 |
| | |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Corporate Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers. SINE™ compounds have also shown biological activity in models of neurodegeneration, inflamma... (more)

Stock Performance



Press Releases [View all]

Jun 23, 2017

Karyopharm Reports Updated Phase 2b
SADAL Data for Selinexor in Diffuse Large B
-Cell Lymphoma at the 2017 European
Hematology Association Annual Meeting

Jun 7, 2017

Karyopharm Doses First Patient in Pivotal
Phase 3 BOSTON Study Evaluating
Selinexor in Patients with
Relapsed/Refractory Multiple Myeloma

May 31, 2017

<u>Karyopharm Therapeutics to Participate in Upcoming Investor Conferences</u>

May 18, 2017

Karyopharm's Phase 2b SADAL Data

<u>Evaluating Selinexor in Diffuse Large B-Cell</u>

<u>Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association</u>

Annual Meeting

May 4, 2017

Karyopharm Reports First Quarter 2017
Financial Results and Highlights Recent
Progress

Financials [View all]

First Quarter Financial Results

Mar 16, 2017 Annual Report (10-K)

Apr 28, 2017 Proxy Statement (DEF 14A)

May 4, 2017

Quarterly Report (10-Q)

Nov 7, 2016

Quarterly Report (10-Q)

Aug 4, 2016

Quarterly Report (10-Q)